|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen J, Xu Y, Tao L, Pan Y, Zhang K, Wang
R, Chen LB and Chu X: miRNA-26a contributes to the acquisition of
malignant behaviors of doctaxel-resistant lung adenocarcinoma cells
through targeting EZH2. Cell Physiol Biochem. 41:583–597. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jonas S and Izaurralde E: Towards a
molecular understanding of microRNA-mediated gene silencing. Nat
Rev Genet. 16:421–433. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rupaimoole R and Slack FJ: MicroRNA
therapeutics: Towards a new era for the management of cancer and
other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Di Leva G, Garofalo M and Croce CM:
MicroRNAs in cancer. Annu Rev Pathol. 9:287–314. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Huang T, Yin L, Wu J, Gu JJ, Wu JZ, Chen
D, Yu HL, Ding K, Zhang N, Du MY, et al: MicroRNA-19b-3p regulates
nasopharyngeal carcinoma radiosensitivity by targeting
TNFAIP3/NF-κB axis. J Exp Clin Cancer Res. 35:1882016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen W, Song J, Bian H, Yang X, Xie X, Zhu
Q, Qin C and Qi J: The functions and targets of miR-212 as a
potential biomarker of cancer diagnosis and therapy. J Cell Mol
Med. 24:2392–2401. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu X, Zhou J, Wu Z, Chen C, Liu J, Wu G,
Zhai J, Liu F and Li G: miR-101-3p suppresses HOX transcript
antisense RNA (HOTAIR)-induced proliferation and invasion through
directly targeting SRF in gastric carcinoma cells. Oncol Res.
25:1383–1390. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hou Y, Li L, Ju Y, Lu Y, Chang L and Xiang
X: miR-101-3p regulates the viability of lung squamous carcinoma
cells via targeting EZH2. J Cell Biochem. 118:3142–3149. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li B, Xie D and Zhang H: MicroRNA-101-3p
advances cisplatin sensitivity in bladder urothelial carcinoma
through targeted silencing EZH2. J Cancer. 10:2628–2634. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yamamoto H, Ngan CY and Monden M: Cancer
cells survive with survivin. Cancer Sci. 99:1709–1714. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pennati M, Folini M and Zaffaroni N:
Targeting survivin in cancer therapy. Expert Opin Ther Targets.
12:463–476. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Greve B, Sheikh-Mounessi F, Kemper B,
Ernst I, Götte M and Eich HT: Survivin, a target to modulate the
radiosensitivity of Ewing's sarcoma. Strahlenther Onkol.
188:1038–1047. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Reichert S, Rödel C, Mirsch J, Harter PN,
Tomicic MT, Mittelbronn M, Kaina B and Rödel F: Survivin inhibition
and DNA double-strand break repair: A molecular mechanism to
overcome radioresistance in glioblastoma. Radiother Oncol.
101:51–58. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Erpolat OP, Gocun PU, Akmansu M, Karakus E
and Akyol G: High expression of nuclear survivin and Aurora B
predicts poor overall survival in patients with head and neck
squamous cell cancer. Strahlenther Onkol. 188:248–254. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Romagnoli M, Séveno C, Bataille R and
Barillé-Nion S: Survivin in cancerology: Molecular aspects and
therapeutic applications. Med Sci (Paris). 24:821–827. 2008.(In
French). View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sprenger T, Rödel F, Beissbarth T, Conradi
LC, Rothe H, Homayounfar K, Wolff HA, Ghadimi BM, Yildirim M,
Becker H, et al: Failure of downregulation of survivin following
neoadjuvant radiochemotherapy in rectal cancer is associated with
distant metastases and shortened survival. Clin Cancer Res.
17:1623–1631. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bjaanaes MM, Halvorsen AR, Solberg S,
Jørgensen L, Dragani TA, Galvan A, Colombo F, Anderlini M,
Pastorino U, Kure E, et al: Unique microRNA-profiles in
EGFR-mutated lung adenocarcinomas. Int J Cancer. 135:1812–1821.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu KH, Zhou B, Lu SH, Feng B, Yang SG, Du
WT, Gu DS, Han ZC and Liu YL: In vitro and in vivo differentiation
of human umbilical cord derived stem cells into endothelial cells.
J Cell Biochem. 100:608–616. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang JH, Li JH, Shao P, Zhou H, Chen YQ
and Qu LH: StarBase: A database for exploring microRNA-mRNA
interaction maps from Argonaute CLIP-Seq and Degradome-Seq data.
Nucleic Acids Res. 39((Database Issue)): D202–D209. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Menyhárt O, Nagy Á and Győrffy B:
Determining consistent prognostic biomarkers of overall survival
and vascular invasion in hepatocellular carcinoma. R Soc Open Sci.
5:1810062018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mariotti LG, Pirovano G, Savage KI, Ghita
M, Ottolenghi A, Prise KM and Schettino G: Use of the γ-H2AX assay
to investigate DNA repair dynamics following multiple radiation
exposures. PLoS One. 8:e795412013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang J, Shen L and Sun LQ: The regulation
of radiosensitivity by p53 and its acetylation. Cancer Lett.
363:108–118. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Véquaud E, Desplanques G, Jézéquel P, Juin
P and Barillé-Nion S: Survivin contributes to DNA repair by
homologous recombination in breast cancer cells. Breast Cancer Res.
Treat. 155:53–63. 2016.
|
|
27
|
Dong Y, Zhang D, Cai M, Luo Z, Zhu Y, Gong
L, Lei Y, Tan X, Zhu Q and Han S: SPOP regulates the DNA damage
response and lung adenocarcinoma cell response to radiation. Am J
Cancer Res. 9:1469–1483. 2019.PubMed/NCBI
|
|
28
|
Yang S, Chen J, Guo Y, Lin H, Zhang Z,
Feng G, Hao Y, Cheng J, Liang P, Chen K, et al: Identification of
prognostic biomarkers for response to radiotherapy by DNA
microarray in nasopharyngeal carcinoma patients. Int J Oncol.
40:1590–1600. 2012.PubMed/NCBI
|
|
29
|
Salim H, Akbar NS, Zong D, Vaculova AH,
Lewensohn R, Moshfegh A, Viktorsson K and Zhivotovsky B: miRNA-214
modulates radiotherapy response of non-small cell lung cancer cells
through regulation of p38MAPK, apoptosis and senescence. Br J
Cancer. 107:1361–1373. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fang H, Xie J, Zhang M, Zhao Z, Wan Y and
Yao Y: miRNA-21 promotes proliferation and invasion of
triple-negative breast cancer cells through targeting PTEN. Am J
Transl Res. 9:953–961. 2017.PubMed/NCBI
|
|
31
|
Thu KL, Chari R, Lockwood WW, Lam S and
Lam WL: miR-101 DNA copy loss is a prominent subtype specific event
in lung cancer. J Thorac Oncol. 6:1594–1598. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li L, Shao MY, Zou SC, Xiao ZF and Chen
ZC: miR-101-3p inhibits EMT to attenuate proliferation and
metastasis in glioblastoma by targeting TRIM44. J Neurooncol.
141:19–30. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bao J, Xu Y, Wang Q, Zhang J, Li Z, Li D
and Li J: miR-101 alleviates chemoresistance of gastric cancer
cells by targeting ANXA2. Biomed Pharmacother. 92:1030–1037. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen LG, Xia YJ and Cui Y: Upregulation of
miR-101 enhances the cytotoxic effect of anticancer drugs through
inhibition of colon cancer cell proliferation. Oncol Rep.
38:100–108. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xu F, Liao JZ, Xiang GY, Zhao PX, Ye F,
Zhao Q and He XX: miR-101 and doxorubicin codelivered by liposomes
suppressing malignant properties of hepatocellular carcinoma.
Cancer Med. 6:651–661. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Altieri DC: Molecular circuits of
apoptosis regulation and cell division control: The survivin
paradigm. J Cell Biochem. 92:656–663. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Altieri DC: Survivin, cancer networks and
pathway-directed drug discovery. Nat Rev Cancer. 8:61–70. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hu S, Qu Y, Xu X, Xu Q, Geng J and Xu J:
Nuclear survivin and its relationship to DNA damage repair genes in
non-small cell lung cancer investigated using tissue array. PLoS
One. 8:e741612013. View Article : Google Scholar : PubMed/NCBI
|
